| x  | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES      EXCHANGE ACT OF 1934  |
|---------|-------------------------------------------------------------------------------------------------|

| o  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE      SECURITIES EXCHANGE ACT OF 1934  |
|---------|-----------------------------------------------------------------------------------------------------|

----

|      |      |                                                                                                            |                |
|----------------|----------------|----------------------------------------------------------------------------------------------------------------------|--------------------------|
| Part I    | Item 1.   | Description of Business                                                                                         |                |
|      | Item 2.   | Description of Property                                                                                         |                |
|      | Item 3.   | Legal Proceedings                                                                                               |                |
|      | Item 4.   | Submission of Matters to a Vote of Security Holders                                                             |                |
|      |      |                                                                                                            |                |
| Part II   | Item 5.   | Market for Common Equity and Related Stockholder      Matters                                                   |                |
|      | Item 6.   | Management’s Discussion and Analysis and Results of Operations and      Financial Condition                    |      |
|      | Item 7.   | Financial Statements                                                                                            |                |
|      | Item 8.   | Changes in and Disagreements with Accountants on Accounting and      Financial Disclosure                       |      |
|      | Item 8A.  | Controls and Procedures                                                                                         |                |
|      | Item 8B.  | Other Information                                                                                               |                |
|      |      |                                                                                                            |                |
| Part III  | Item 9.   | Directors, Executive Officers, Promoters and Control Persons,      Compliance with Section 16(a) of the Exchange Act |      |
|      | Item 10.  | Executive Compensation                                                                                          |                |
|      | Item 11.  | Security Ownership of Certain Beneficial Owners and      Management                                             |                |
|      | Item 12.  | Certain Relationships and Related Party Transactions                                                            |                |
|      | Item 13.  | Exhibits                                                                                                        |                |
|      | Item 14.  | Principal Accountant Fees and Services                                                                          |                |

----

Further, this report contains forwardlooking statements within the meaning of Section 27A of the Securities Act andSection 21E of the Securities Exchange Act that involve substantial risks anduncertainties.  Such statements include, without limitation, all statementsas to expectation or belief and statements as to the Company’s future results ofoperations, the progress of any research, product development and clinicalprograms, the need for, and timing of, additional capital and capitalexpenditures, partnering prospects, the protection of and the need foradditional intellectual property rights, effects of regulations, the need foradditional facilities and potential market opportunities.  The Company’sactual results may vary materially from those contained in such forward-lookingstatements because of risks to which the Company is subject, such as lack ofavailable funding, competition from third parties, intellectual property rightsof third parties, regulatory constraints, litigation and other risks to whichthe Company is subject.

----

ITEM 1. DESCRIPTIONOF BUSINESS

| ·                 | provide enough data      for statistical proof of safety and efficacy;  |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------|
| ·                 | compare the      experimental therapy to existing therapies;            |
| ·                 | uncover any      unexpected safety problems, such as side-effects; and  |
| ·                 | generate product      labeling.                                         |

ITEM 2. DESCRIPTIONOF PROPERTY

ITEM 3. LEGALPROCEEDINGS

ITEM 4. SUBMISSIONOF MATTERS TO A VOTE OF SECURITY HOLDERS 

----

ITEM 5. MARKET FORCOMMON EQUITY AND RELATED STOCKHOLDER MATTERS

ITEM 6. MANAGEMENT’SDISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS AND FINANCIALCONDITION

----

ITEM 7. FINANCIALSTATEMENTS

----

|                                                                                                         |   |      |    |          |   |   |
|--------------------------------------------------------------------------------------------------------------|--------|-----------|---------|---------------|--------|--------|
|                                                                                                         |   | March 31, |    |
|                                                                                                         |   | 2006      |    |          | 2005   |   |
|                                                                                                         |   |      |    |          |   |   |
| ASSETS                                                                                                  |   |      |    |          |   |   |
|                                                                                                         |   |      |    |          |   |   |
| Currentassets:                                                                                          |   |      |    |          |   |   |
|     Cash and      cash equivalents                                                       |   | $         | 1,944   |          |   | $      | -- |   |
| Total assets                                                                                            |   | $         | 1,944   |          |   | $      | -- |   |
|                                                                                                         |   |      |    |          |   |   |   |   |
| LIABILITIES AND      SHAREHOLDERS' DEFICIT                                                              |   |      |    |          |   |   |   |   |
|                                                                                                         |   |      |    |          |   |   |   |   |
| Current      liabilities:                                                                               |   |      |    |          |   |   |   |   |
|     Accounts      payable                                                                |   | $         | 32,184  |          |   | $      | 1,792 |   |
|     Accrued      liabilities                                                             |   |      | 12,500  |          |   |   | -- |   |
|         Total current      liabilities                               |   |      | 44,684  |          |   |   | 1,792 |   |
| Commitments and      contingencies                                                                      |   |      | --      |          |   |   | -- |   |
| Shareholders'      deficit:                                                                             |   |      |    |          |   |   |   |   |
|          Preferred stock, no par value, 10,000,000 shares authorized,                    |   |      |    |          |   |   |   |   |
|       no shares issued or      outstanding                                     |   |      | --      |          |   |   | -- |   |
|     Common      stock, no par value, 500,000,000 shares authorized,                      |   |      |    |          |   |   |   |   |
|       81,352,500 issued and outstanding      at March  31, 2006 and 2005  |   |      | 1,000   |          |   |   | 1,000 |   |
|     Stock      subscription receivable                                                   |   |      | --      |          |   |   | (1,000 | )        |
|     Deficit      accumulated in the development stage                                    |   |      | (43,740 | )        |   |   | (1,792 | )        |
|          Total      shareholders’ deficit                 |   |      | (42,740 | )        |   |   | (1,792 | )        |
| Total liabilities and      shareholders' deficit                                                        |   | $         | 1,944   |          |   | $      | -- |   |

----

|                                                            |   |           |       |          | Inception              |   |       | Inception              |   |
|-----------------------------------------------------------------|--------|----------------|------------|---------------|------------------------|--------|------------|------------------------|--------|
|                                                            |   | Year Ended     |       |          | (February 15, 2005) to |   |       | (February 15, 2005) to |   |
|                                                            |   | March 31, 2006 |       |          | March 31, 2005         |   |       | March 31, 2006         |   |
|                                                            |   |           |       |          |                   |   |       |                   |   |
| General and administrative      expenses                   |   | $              | 41,948     |          |                   | $      | 1,792      |                   |   | $ | 43,740 |   |
| Net loss                                                   |   | $              | (41,948    | )        |                   | $      | (1,792     | )                 |   | $ | (43,740 | )        |
|                                                            |   |           |       |          |                   |   |       |                   |   |   |   |   |
| Net loss per      share:                                   |   |           |       |          |                   |   |       |                   |   |   |   |   |
| Basic and      diluted                                     |   | $              | --         |          |                   | $      | --         |                   |   |   |   |   |
|                                                            |   |           |       |          |                   |   |       |                   |   |   |   |   |
| Weighted average number of      common shares outstanding  |   |           |       |          |                   |   |       |                   |   |   |   |   |
|                                                            |   |           |       |          |                   |   |       |                   |   |   |   |   |
| Basic and      diluted                                     |   |           | 81,352,500 |          |                   |   | 61,860,837 |                   |   |   |   |   |

----

|                                                                                  |   |   |       |   |   |   |        |         |   |   | Deficit     |     |   |   |     |
|---------------------------------------------------------------------------------------|--------|--------|------------|--------|--------|--------|-------------|--------------|--------|--------|-------------|----------|--------|--------|----------|
|                                                                                  |   |   |       |   |   |   |        |         |   |   | Accumulated |     |   |   |     |
|                                                                                  |   |   |       |   |   |   |        | Stock        |   |   | During the  |     |   |   |     |
|                                                                                  |   |   |       |   |   |   |        | Subscription |   |   | Development |     |   |   |     |
|                                                                                  |   | Shares |       |   | Amount |   |        | Receivable   |   |   | Stage       |     |   | Total  |     |
| Balance – February 15,      2005          (Inception)  |   |   | 73,000,000 |   |   | $      | 1,000       |         |   | $      | (1,000      | )   |   | $      |  -- |   |   | $ |  -- |   |
| Recapitalization                                                                 |   |   | 8,352,500  |   |   |   | --          |         |   |   | --          |     |   |   | --       |   |   |   | -- |   |
| Net loss for the year      ended    March 31,      2005           |   |   | --         |   |   |   | –     |         |   |   | --          |     |   |   | (1,792   | )   |   |   | (1,792 | )   |
| Balance – March 31,      2005                                              |   |   | 81,352,500 |   |   |   | 1,000       |         |   |   | (1,000      | )   |   |   | (1,792   | )   |   |   | (1,792 | )   |
| Collection of stock      subscription          receivable    |   |   | --         |   |   |   | --          |         |   |   | 1,000       |     |   |   | --       |   |   |   | 1,000 |   |
| Net loss for the year      ended     March      31, 2006     |   |   | --         |   |   |   | –     |         |   |   | --          |     |   |   | (41,948  | )   |   |   | (41,948 | )   |
| Balance – March 31,      2006                                              |   |   | 81,352,500 |   |   | $      |  1,000 |         |   | $      | --          |     |   | $      | (43,740  | )   |   | $ | (42,740 | )   |

----

|                                                                                                                                         |                                    | Inception                                                                   | Inception                               |   |
|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------|--------|
|                                                                                                                                         | Year      Ended                         | (February      15, 2005)                                                    | (February      15, 2005)                |   |
|                                                                                                                                         | March      31, 2006                     | to      March 31, 2005                                                      | to      March 31, 2006                  |   |
| Cash      flows from operating activities:                                                                                                   |                                    |                                                                        |                                    |   |
|     Net      loss                                                                                                        | $     (41,948) | $     (1,792)                                      | $     (43,740) |   |
|     Adjustments      to reconcile net loss to cash used in      operating      activities: |                                    |                                                                        |
|         Changes      in assets and liabilities:                                                      |                                    |                                                                        |                                    |   |
|             Accounts      payable and accrued liabilities                        | 42,892                                  | 1,792                                                                       | 44,684                                  |   |
| Net      cash provided by operating activities                                                                                               | 944                                     | --                                                                          | 944                                     |   |
| Cash      flows from investing activities                                                                                                    | --                                      | --                                                                          | --                                      |   |
| Cash      flows from financing activities:                                                                                                   |                                    |                                                                        |                                    |   |
|     Collection      of stock subscription receivable                                                                     | 1,000                                   | --                                                                          | 1,000                                   |   |
| Net      cash provided by financing activities                                                                                               | 1,000                                   | --                                                                          | 1,000                                   |   |
| Net      increase in cash                                                                                                                    | 1,944                                   | --                                                                          | 1,944                                   |   |
| Cash      and cash equivalents, beginning of period                                                                                          | --                                      | --                                                                          | --                                      |   |
| Cash      and cash equivalents, end of period                                                                                                | $     1,944    | $            -- | $     1,944    |   |

| Supplemental      cash flow information:                   |                                                                        |                                                                        |                                                                        |
|------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
|     Interest      paid                 | $            -- | $            -- | $            -- |
|     Taxes      paid                    | $            -- | $            -- | $            -- |
|                                                       |                                                                        |                                                                        |                                                                        |
|     Stock      subscription receivable | $            -- | $     1,000                                        | $            -- |

----

|                                                     |   | March 31, 2006 |    |
|----------------------------------------------------------|--------|----------------|---------|
| Deferred tax assets attributable to:                |   |           |    |
|     Net operating loss carryforward  |   | $              | 14,872  |   |
| Less:  Change in valuation allowance           |   |           | (14,872 | )        |
| Net deferred tax assets                             |   | $              | --      |   |

ITEM 8. CHANGES IN AND DISAGREEMENTSWITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 Child Sullivan has not prepared an audit report onInteractive Therapeutics, Inc.

ITEM 8A. CONTROLSAND PROCEDURES

Changes in Internal Controls over FinancialReporting

ITEM 8B. OTHERINFORMATION

ITEM 9.

| Name                   | Age  | Position                                                                                            |
|-----------------------------|-----------|----------------------------------------------------------------------------------------------------------|
| J.      Leonard Ivins  | 71   | Chief      Executive Officer, Principal Accounting Officer, Secretary, Treasurer and      Director  |
| Brad      Serres       | 10   | Director                                                                                            |

Brad Serres

Independence of Directors & BoardCommittees

Code of Ethics

ITEM10.

|   Name and      Address of Beneficial Owner                                                                                                           | Number of      Shares of Common Stock Beneficially Owned  |   Percentage Of      Class    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------|
| Beneficial Owners of more than 5%:                                                                                                                              |                                                      |                                                   |
|      Silver Star Holdings Trust (1)                                                                                                         | 66,430,000                                                | 81.7%                                                  |
|      Carl A. Chase (2)                                                                                                                      | 6,570,000                                                 | 8.1%                                                   |
|                                                                                                                                                            |                                                      |                                                   |
| Named Executive Officers and Directors:                                                                                                                         |                                                      |                                                   |
|      J. Leonard Ivins (3)                                                                                                                   | --                                                        | --                                                     |
|      Brad Serres (4)                                                                                                                        | --                                                        | --                                                     |
|      All directors & executive      officers             as a group (2 persons)  | --                                                        | --                                                     |

| Exhibit No.  | Description                                                                                                                                                                                                                                                                               |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1          | Articles of Incorporation (incorporated by reference to Exhibit      3.1 from Registration Statement on Form-SB filed with the Securities and      Exchange Commission on October 11, 2000)                                                                                               |
| 3.2          | Bylaws of Tabatha I, Inc. (incorporated by reference to Exhibit      3.2 from Registration Statement on Form-SB filed with the Securities and      Exchange Commission on October 11, 2000)                                                                                               |
| 4.1          | Specimen of Stock Certificate (incorporated by reference to      Exhibit 4.1 from Registration Statement on Form-SB filed with the      Securities and Exchange Commission on October 11, 2000)                                                                                           |
| 4.2          | Specimen Class A Convertible Preferred Stock Certificate      (incorporated by reference to Exhibit 4.2 from Registration Statement on      Form-SB filed with the Securities and Exchange Commission on October 11,      2000)                                                           |
| 14.1         | Code of Ethics (incorporated by reference to Exhibit 14.1 to      Registrant’s Form 10-KSB filed with the Securities and Exchange Commission      on June 29, 2005)                                                                                                                 |
| 10.1         | Exchange Agreement between Interactive Therapeutics, Inc.      (formerly Tabatha I, Inc.) and Zigen, Inc. dated February 25, 2005      (incorporated by reference to Exhibit 10.1 to Registrant’s Form 8-K filed      with the Securities and Exchange Commission of May 31, 2005)  |
| 31.1         | Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the      Securities Exchange Act of 1934, as amended (filed herewith)                                                                                                                                                         |
| 32.1         | Certification pursuant to 18 U.S.C. Section 1350, as adopted      pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed      herewith)                                                                                                                                         |
|         |                                                                                                                                                                                                                                                                                      |

ITEM14.              PRINCIPAL ACCOUNTANT FEES AND SERVICES

| Signature                                                                                                        | Title                                                                                          | Date         |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------|
| By:  /s/  J. Leonard      Ivins         J. Leonard      Ivins  | Chief Executive Officer, Principal Accounting Officer, Secretary,      Treasurer and Director  | May 5, 2008       |
|                                                                                                   |                                                                                           |         |
| By:  /s/  Brad      Serres                                                                             | Director                                                                                       | May 5, 2008  |
|         BradSerres                                                            |                                                                                           |         |

----

| Exhibit No.  | Description                                                                                                                                                                                                                                                                               |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1          | Articles of Incorporation (incorporated by reference to Exhibit      3.1 from Registration Statement on Form-SB filed with the Securities and      Exchange Commission on October 11, 2000)                                                                                               |
| 3.2          | Bylaws of Tabatha I, Inc. (incorporated by reference to Exhibit      3.2 from Registration Statement on Form-SB filed with the Securities and      Exchange Commission on October 11, 2000)                                                                                               |
| 4.1          | Specimen of Stock Certificate (incorporated by reference to      Exhibit 4.1 from Registration Statement on Form-SB filed with the      Securities and Exchange Commission on October 11, 2000)                                                                                           |
| 4.2          | Specimen Class A Convertible Preferred Stock Certificate      (incorporated by reference to Exhibit 4.2 from Registration Statement on      Form-SB filed with the Securities and Exchange Commission on October 11,      2000)                                                           |
| 14.1         | Code of Ethics (incorporated by reference to Exhibit 14.1 to      Registrant’s Form 10-KSB filed with the Securities and Exchange Commission      on June 29, 2005)                                                                                                                 |
| 10.1         | Exchange Agreement between Interactive Therapeutics, Inc.      (formerly Tabatha I, Inc.) and Zigen, Inc. dated February 25, 2005      (incorporated by reference to Exhibit 10.1 to Registrant’s Form 8-K filed      with the Securities and Exchange Commission of May 31, 2005)  |
| 31.1         | Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the      Securities Exchange Act of 1934, as amended (filed herewith)                                                                                                                                                         |
| 32.1         | Certification pursuant to 18 U.S.C. Section 1350, as adopted      pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed      herewith)                                                                                                                                         |

----

Exhibit 31.1

```
Certification Pursuant to
```

```
Section 302 of the sarbanes-oxley Act
```

```
 
```

```
        I, J. Leonard Ivins, as chief executive officer, certify that:  
```

    - I have reviewed this annual report on Form 10-KSB of  Interactive Therapeutics, Inc. (the “small business issuer);  
    - Based on my knowledge, this report does not contain any  untrue statement of a material fact or omit to state a material fact necessary  to make the statements made, in light of the circumstances under which such  statements were made, not misleading with respect to the period covered by  this report;  
    - Based on my knowledge, the financial statements, and other  financial information included in this report, fairly present in all material  respects the financial condition, results of operations and cash flows of the  small business issuer as of, and for, the periods presented in this report;   
    - The small business issuer's other certifying officer(s) and  I are responsible for establishing and maintaining disclosure controls and  procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and  internal control over financial reporting (as defined in Exchange Act Rules  13a-15(f) and 15d-15(f)) for the small business issuer and have:  
    -        - Designed such disclosure controls and procedures, or    caused such disclosure controls and procedures to be designed under our    supervision, to ensure that material information relating to the small    business issuer, including its consolidated subsidiaries, is made known to    us by others within those entities, particularly during the period in which    this report is being prepared;  
      - Designed such internal control over financial reporting,    or caused such internal control over financial reporting to be designed    under our supervision to provide reasonable assurance regarding the    reliability of financial reporting and the preparation of financial    statements for external purposes in accordance with generally accepted    accounting principles.  
      - Evaluated the effectiveness of the small business issuer's    disclosure controls and procedures and presented in this report our    conclusions about the effectiveness of the disclosure controls and    procedures, as of the end of the period covered by this report based on such    evaluation; and  
      - Disclosed in this report any change in the small business    issuer's internal control over financial reporting that occurred during the    small business issuer's fourth fiscal quarter that has materially affected,    or is reasonably likely to materially affect, the small business issuer's    internal control over financial reporting; and 
    - The small business issuer's other certifying officer(s) and  I have disclosed, based on our most recent evaluation of internal control over  financial reporting, to the small business issuer's auditors and the audit  committee of the small business issuer's board of directors (or persons  performing the equivalent functions):   
    -        - All significant deficiencies and material weaknesses in    the design or operation of internal control over financial reporting which    are reasonably likely to adversely affect the small business issuer's    ability to record, process, summarize and report financial information;    and         - Any fraud, whether or not material, that involves    management or other employees who have a significant role in the small    business issuer's internal control over financial reporting. 
```
Date: May 5, 2008
```

```
 
```

----

```
Certification Pursuant to
```

```
Section 302 of the sarbanes-oxley Act
```

```
         I, J. Leonard Ivins, as principal accounting officer, certify that: 
```

```
/s/ J. Leonard Ivins                               
```

```
J. Leonard Ivins, Principal Accounting Officer
```

```
Date: May 5, 2008
```

----

```
/s/ J. Leonard Ivins            
```

```
Date: May 5, 2008
```

----

----

```
 
```

```
Date: May 5, 2008
```